Research Article
The Prevalence of Cardiac Risk Factors in Men with Localized Prostate Cancer Undergoing Androgen Deprivation Therapy in British Columbia, Canada
Table 1
Baseline characteristics of 100 men referred for androgen deprivation therapy.
| Age at diagnosis | 73 (50–87) | Vascular disease | 25 (25%) | Coronary artery disease | 17 (17%) | Percutaneous coronary intervention | 9 (9%) | Coronary artery bypass surgery | 5 (5%) | Stroke | 7 (7%) | Peripheral arterial disease | 5 (5%) | Atrial fibrillation | 5 (5%) | Supraventricular tachycardia | 1 (1%) | Arrhythmia, not specified | 4 (4%) | Cardiac pacemaker | 1 (1%) | Pericarditis | 1 (1%) | Coronary vasospasm | 1 (1%) | History of heart failure | 1 (1%) | Framingham risk category | | High risk | 49 (65%)* | Intermediate risk | 25 (33%)* | Low risk | 1 (1%)* | Gleason score | | Moderately differentiated (5–7) | 30 (30%) | Poorly differentiated (8–10) | 70 (70%) | Clinical stage | | T1 | 27 (27%) | T2 | 43 (43%) | T3 | 23 (23%) | T4 | 3 (3%) | X | 4 (4%) | Initial PSA (ng/mL) | | <5 | 9 (9%) | 5–10 | 29 (29%) | >10 | 62 (62%) | Updated Charlson Comorbidity Index | | 0 | 82 (82%) | 1 | 14 (14%) | ≥2 | 4 (4%) | Hormonal treatment used | | Goserelin | 72 (72%) | Leuprolide | 25 (25%) | Degarelix | 2 (2%) | Bicalutamide | 92 (92%) | Buserelin | 1 (1%) | Flutamide | 1 (1%) |
|
|
Expressed as median (range) or number (percentage). *Expressed as percentage of patients without baseline history of vascular disease.
|